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Abstract
Background: Enterococci are frequent pathogens causing nosocomial infections in Germany. Infections due to
strains with vancomycin resistance are high when compared with other European states. Therefore, the study
aimed to describe the recent progression of nosocomial infections due to vancomycin-resistant enterococci
(VRE) in Germany.
Methods: We analyzed data from two components of the German national nosocomial infection surveillance
system for the period 2007–2016. For primary bloodstream infections (BSIs) and urinary tract infections (UTIs)
we used data from intensive care units and for surgical site infections (SSIs) data from surgical departments.
In a sensitivity analysis, we considered only data from participants that participated continuously from 2007 to
2016 (“core group”). We calculated proportions of VRE among all nosocomial enterococcal infections with 95%
confidence intervals (95% CIs) and trends over time. A multivariable logistic regression was used to compare
occurrence of VRE proportions among German federal states.
Results: Enterococcal infections from 857 ICUs and 1119 surgical departments were analyzed. On ICUs, the proportion
of vancomycin resistance in enterococci causing nosocomial infections significantly increased for BSIs from 5.9 to 16.7%
and for UTIs from 2.9 to 9.9%; for surgical site infections, the proportion of VRE increased from 0.9 to 5.2% (P < 0.001 for
all). In the core group, the increase of VRE was more pronounced in ICUs (BSIs: 5.5 to 21.6%; UTIs: 2 to 11.2%) but was
not seen in surgical departments (SSIs: 1.5 to 2.8%). Compared with the most populous German federal state North
Rhine Westphalia, enterococcal infections in Hesse (Odds Ratio (OR) 2.3, 95% CI 1.7–3.1), Saxony (OR 2.5, 95% CI 1.8–3.5)
and Thuringia (OR 1.9, 95% CI 1.4–2.6) were more likely to be caused by vancomycin-resistant strains.
Conclusion: In Germany, the proportion of VRE in nosocomial infection due to enterococci is still increasing. It remains
unclear, why a large variation in the proportion of VRE exists between German federal states.
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Background
Vancomycin-resistant enterococci (VRE) have emerged as
important multiresistant pathogens causing nosocomial
infections [1, 2]. Infections with VRE are associated with
increased length of stay and excess in-hospital mortality
and therefore pose a rising public health threat [3]. In
2017, the World Health Organization identified VRE as
one of the most important resistant bacteria in their
“Global Priority list of antibiotic-resistant bacteria list” [4].
According to the 2016 surveillance report of the Euro-
pean Antimicrobial Resistance Network (EARS-Net), a
significant increasing trend for VRE between 2013 and
2016 was not identified among invasive isolates for the
EU/EEA population-weighted mean percentage [5]; how-
ever, in seven out of 30 participating countries a signifi-
cant increase of VRE was observed. Ireland (VRE rate of
44.1%), Greece (27.9%), Slovakia (26.4%), Poland (25.2%)
and Hungary (22.5%) showed the highest resistance rates
in the EARS-Net 2016 report, if only countries with
more than 100 reported isolates were considered. In
Germany, the proportion of VRE among invasive Entero-
coccus (E.) faecium isolates was 12.1% and comparable
with the EU/EEA mean.
Previously, we observed a dramatic increase of the
proportion of VRE among blood-stream infections and
surgical site infections between 2007 and 2012 [6].
Therefore, the objective of this study was to investigate
the recent development of different nosocomial infec-
tions caused by VRE in Germany by using data from
the large German national nosocomial infection surveil-
lance system.
Methods
We analyzed data that were recorded into two surveil-
lance components of the German national nosocomial
infection surveillance system (Krankenhaus-Infektions-
Surveillance-System, KISS) between 2007 and 2016.
Detailed information on KISS and its above-mentioned
components have been described elsewhere [7]. Briefly,
data on nosocomial primary blood stream-infections
(BSI) and nosocomial urinary tract-infections (UTIs) on
intensive care units (ICUs) were recorded in the ICU
component of KISS (ICU-KISS). Data on nosocomial
surgical site infections (SSIs) on surgical departments
were recorded in OP-KISS. Infections were documented
according to definitions by the CDC [8]. In KISS, entero-
coccal infections are not documented on a species level.
Therefore, the term VRE is defined as all infections due
to enterococci resistant against vancomycin regardless of
the underlying mechanism or species.
Ethics and data protection
We analyzed aggregated and anonymous data that are
collected by the participating hospitals in accordance
with the German “Protection against Infection Act” §23.
Therefore, ethical approval by an institutional board was
not necessary.
Statistical analysis
We pooled data recorded in ICU-KISS and OP-KISS
and analyzed the proportion of VRE for each type of in-
fection (BSI, UTI, SSI) by dividing the number of entero-
coccal infections resistant against vancomycin by the
number of all enterococcal infections multiplied by 100.
95% confidence intervals (CIs) were calculated. Data
were univariate tested for a yearly linear trend by using
Cochrane-Armitage-test [6].
A multivariable logistic regression was used to com-
pare VRE proportions among German federal states. In
addition to the risk factor federal state, the following po-
tential confounders were considered: year of the surgical
procedure, gender and age group for the patient (0–50,
51–65, 66–70 and 71–120 years), type of hospital (uni-
versity hospital, other hospital), season, type of ICU or
type of surgical department, and hospital size (400 beds
and ≥ 400 beds). Stepwise forward-backward selection
was used to derive the final logistic regression model.
Parameters were entered into the model at a significance
level of P ≤ 0.05 and were removed at P > 0.05. Odds
Ratios (OR) with 95% CIs were calculated.
Since not all hospitals reported data for the entire
study period, we conducted a sensitivity analysis in
which only hospitals were included that had reported
data continuously from 2007 to 2016 for at least 6 month
per year (“core group”). P-values less than 0.05 were
considered statistically significant.
All analyses were performed with R 3.4.3 [R Core
Team (2013); R Foundation for statistical computing,
Vienna, Austria] and SAS 9.4 (SAS Institute Inc., Cary,
NC, USA).
Results
Between 2007 and 2016 a total of 1121 ICUs and 1412
surgical departments from all German federal states re-
ported data on nosocomial infections to ICU-KISS and
OP-KISS, respectively (Table 1). Of those, 12,659 infec-
tions were due to enterococcus species. Overall, the
proportion of VRE increased from 1.4% in 2007/2008
to 10% in 2015/2016 (Fig. 1). In BSI, the proportion of
VRE increased from 5.9 to 16.7% (P < 0.001). Among
UTIs and SSIs, the proportion of VRE increased from
2.9 to 9.9% (P < 0.001) and from 0.9 to 5% (P < 0.001),
respectively (Table 2).
According to our sensitivity analysis, 218 ICUs and
174 surgical wards reported data continuously on an an-
nual basis (core group). Overall, the core group showed
a comparable increase regarding the proportion of VRE
from 4 to 10%; however, the increase in the core group
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was more pronounced in BSIs and UTIs whereas the
proportion of VRE among SSI showed only a small in-
crease (Fig. 2). VRE proportions increased significantly
in primary BSI from 5.5 to 21.6% (P < 0.001) and in UTI
from 2 to 11.2% (P = 0.001).
Regarding differences in the proportion of VRE among
German federal states, we found that proportion of VRE
infections were > 10% in the 6 federal states of Berlin,
Hesse, Saarland, Saxony-Anhalt, Saxony and Thuringia,
all of which are in the center of Germany (Fig. 3). Com-
pared with the most populous federal state North Rhine
Westphalia, enterococcal infections in Hesse (OR 2.3,
95% CI 1.7–3.1), Saxony (OR 2.5, 95% CI 1.8–3.5) and
Thuringia (OR 1.9, 95% CI 1.4–2.6) were more likely to
be caused by VRE. Additionally, the final multivariable
logistic regression indicated that type of hospital (univer-
sity hospital vs. non-university hospital: OR 2.1, 95% CI
1.7–2.5), type of ICU (internal medicine ICU vs. non-
internal medicine ICU: OR: 1.8 (95% CI 1.5–2.2) and
calendar year (OR 1.1, 95% CI 1.1–1.2) statistically sig-
nificant increased the chance for VRE.
Discussion
Our analysis of the German national nosocomial infec-
tion surveillance system revealed a continuous increase
of VRE proportions in nosocomial infections caused by
enterococci in Germany between 2007 and 2016. This
development has become even more apparent since our
last report [6].
The results on VRE are concordant with other reports
from Germany. Behnke et al. showed in two consecutive
national point prevalence studies that vancomycin resist-
ance in E. faecium causing nosocomial infections in-
creased from 10.2% in 2011 to 23.1% in 2016 [9, 10].
Another study which analyzed data on antibiotic con-
sumption and antimicrobial resistance in German ICUs
Table 1 ICUs and surgical departments providing VRE infection data for 2007–16 per year from the German national nosocomial
infection surveillance system (KISS)
Year/number (n) 2007/08 2009/10 2011/12 2013/14 2015/16 Totala
Number (n) of ICUs 465 533 645 764 857 1121
Number (n) of surgical departments 432 558 681 919 1119 1412
Nosocomial enterococcal infections
Total number (N) of nosocomial enterococcal infections 2047 2559 2253 2639 3161 12,659
Number of VRE infections, n (% (n/N)) 79 (3.9) 106 (4.1) 143 (6.4) 187 (7.1) 318 (10.1) 833 (6.6)
Total number (N) of enterococcal infections on ICUs 1520 1927 1574 1700 1929 8650
Number of VRE infections on ICUs, n (% (n/N)) 74 (4.9) 90 (4.7) 119 (7.6) 158 (9.3) 229 (11.9) 670 (7.8)
Total number (N) of nosocomial enterococcal infections
in surgical wards
527 637 679 939 1232 4009
Number of nosocomial VRE infections in surgical wards,
n (% (n/N))
5 (1.0) 16 (2.5) 24 (3.5) 30 (3.2) 57 (4.6) 132 (3.3)
ICU intensive care unit, VRE vancomycin-resistant enterococci; a Total number of ICUs/surgical departments that reported data for at least 6 month in any year
Fig. 1 Time trend for percentage of vancomycin-resistant entercoccal (VRE) infections according to the German national nosocomial infection
surveillance system (KISS), by infection site
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found a continuous increase in resistance against vanco-
mycin in E. faecium between 2001 and 2016 [11]. Finally,
comparable results were found in the national anti-
microbial resistance surveillance project [12], where
detection of E. faecium derived from blood-cultures
has increased by up to 50% in recent years and pro-
portion of isolates resistant against vancomycin in-
creased to 11.9% [13].
Interestingly, the recent report by the EARS-net de-
scribed a high but stable situation regarding the propor-
tion of VRE among E. faecium isolates of 12.1% in
Germany, which is comparable with the European popula-
tion weighted mean of 11.8% for 2016 [5]. These differ-
ences might be caused by the following reasons. (i) In
EARS-Net, a static representative sample of hospitals from
defined regions deliver rates of BSI from all wards based
on laboratory results whereas in KISS a continuously
growing sample of hospitals and individual wards report
different types of infections (UTIs, SSIs and BSIs). How-
ever, even when considering only ICUs that continuously
reported data on BSI we observed a continuous increase
of VRE. (ii) As compared to EARS-net, we considered not
only BSI but also surgical site infections and urinary tract
infections. However, when only BSI were analysed in our
study, the increase in the last 3 years has been particularly
pronounced and differences to EARS-Net data remain un-
clear. (iii) Antimicrobial susceptibility testing (AST) in
many microbiological laboratories Germany was per-
formed according to Clinical & Laboratory Standards In-
stitute (CLSI) while EARS-net uses EUCAST-standards
only [14]. This potentially could influence vancomycin re-
sistance rates especially in low and medium-level resist-
ance due to differing recommended AST methods and
clinical breakpoints [15].
Table 2 Data on nosocomial infections due to Enterococci for 2007–16 per year from the German national nosocomial infection
surveillance system (KISS), by infection site
Surgical site infections Bloodstream infections Urinary tract infections
Year Enterococci
(n)








VRE (n) Proportion in %
(95% CI)
2007 231 2 0.87 (0.15, 2.83) 170 10 5.88 (3.03, 10.23) 450 13 2.89 (1.62, 4.78)
2008 296 3 1.01 (0.26, 2.73) 206 15 7.28 (4.29, 11.47) 540 29 5.37 (3.69, 7.52)
2009 301 7 2.33 (1.02, 4.55) 273 23 8.42 (5.55, 12.18) 591 19 3.21 (2.00, 4.88
2010 336 9 2.68 (1.31, 4.86) 261 20 7.66 (4.88, 11.38) 627 26 4.15 (2.78, 5.93)
2011 357 11 3.08 (1.63, 5.29) 303 32 10.56 (7.46, 14.41) 379 18 4.75 (2.93, 7.26)
2012 322 13 4.04 (2.26, 6.63) 265 33 12.45 (8.88, 16.85) 434 27 6.22 (4.22, 8.80)
2013 420 20 4.76 (3.02, 7.13) 338 30 8.88 (6.18, 12.27) 462 37 8.01 (5.79, 10.76)
2014 519 10 1.93 (0.98, 3.41) 335 30 8.96 (6.24, 12.38) 439 44 10.02 (7.47, 13.10)
2015 615 26 4.23 (2.84, 6.05) 409 57 13.94 (10.83, 17.55) 504 41 8.13 (5.98, 10.77)
2016 617 31 5.02 (3.50, 6.97) 437 73 16.70 (12.39, 18.90) 496 49 9.88 (7.48, 12.75)
VRE vancomycin-resistant enterococci
Fig. 2 Time trend for percentage of vancomycin-resistant enterococcal (VRE) infections according to the German national nosocomial infection
surveillance system (KISS), by infection site. Data from wards that participated continuously from 2007 to 2016 (“core group”)
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Risk factors that have been described for VRE
colonization or infections are long periods of hospitalization,
hemodialysis, immunosuppression as well as close proximity
to patients infected or colonized with VRE [16]. The fact
that enterococci are able to survive on environmental sur-
faces for long periods of time [16, 17] highlights the import-
ance of adherence to hand hygiene practice to prevent
transmission. But despite improved adherence to hand-
hygiene and successful reduction of nosocomial infections
in Germany [18, 19], VRE continues to gain importance
when compared to other multidrug resistant gram-positive
organisms [11].
Increased antibiotic consumption has been advocated as
another important risk factor that influence spread of
VRE [16, 20, 21]. Many reports have established an indir-
ect or direct link between appearance of VRE and the
consumption of certain antimicrobial groups but the
connection probably is more complex [21]. Exposure to
substances with a broad gram-negative and anerobic
microbiological spectrum, but no coverage against E. fae-
cium are believed to facilitate the colonization of the
GI-tract with VRE [22]. Particularly carbapenems [20], 3rd
generation cephalosporins [23] but also penicillin’s with
beta-lactamase inhibitors such as piperacillin/tazobactam
[24] are likely to trigger this process. In Germany, cepha-
losporins are now the most commonly prescribed in
German primary care [25] and might have triggered VRE-
selection in the outpatient setting already. This would
highlight the need of antibiotic stewardship not only in
the inpatient but also in the outpatient setting [26, 27].
Interestingly, a recent meta-analysis has not found a direct
influence of measures within in-hospital antimicrobial
stewardship and the occurrence of VRE; however, the
number of included studies was limited [28].
Although differences of VRE are obviously among
European countries [5], only few studies have assessed
regional differences of VRE within the same country. In
a Canadian study, in which the molecular epidemiology
of VRE from invasive samples from the National
Nosocomial Infection Surveillance Program (CNISP)
was analyzed found an increase of VRE in western and
central Canada [29]. The authors assumed that the
clonal spread of certain sequence types might have been
in part responsible for these findings, although a reliable
explanation was not possible. Kullar et al. evaluated re-
gional variations on VRE across blood, urine and wound
sources in United States Hospitals 2015 and found sig-
nificant differences among US states [30]. A potential
explanation for these results was not discussed.
The reasons for the regional differences in our study
are also unclear and possible reasons for higher VRE
rates in the center of Germany are difficult to explain
and are likely to be multifactorial [6]. One possible
explanation might be regional variations in antibiotic
usage in the ambulatory and/or the inpatient setting; for
example, a large population-based study found among
German federal states differences in outpatient antibiotic
prescription rates [25] of fluoroquinolones and cephalos-
porines, substances that might influence VRE selection
process [1, 16, 22]. Other reasons for the regional differ-
ences that have been discussed are differences in the
proportion of VRE in the environment (e.g. higher pro-
portion of VRE in farm animals) or the spread of new or
clonal VRE strain in certain areas [6]. However, Willems
et al. found genetic differences in hospital-acquired VRE
isolates and community-acquired or animal isolates
which makes an association between the environment
and increased VRE rates in German ICUs unlikely [31].
Some limitations have to be acknowledged: (i) Since
fulfillment of case criteria depends on diagnostic sam-
pling and documentation there is a risk for underdetec-
tion of cases. However, using proportions of VRE for all
nosocomial infections caused by enterococci might have
reduce confounding effects for changes in the bacterio-
logical diagnostic over time, since only pathogen-derived
infections were included. (ii) We did not record below a
genus level of enterococci; therefore, we were unable to
rule out an increase of Enterococcus spp. with intrinsic
Fig. 3 Distribution of the proportion of vancomycin-resistant entercoccal (VRE) infections among German federal states according to data from
the German national nosocomial infection surveillance system (KISS) 2007–2016
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glycopeptide resistance. However, this is less likely
since national and international sources have reported
an increase vancomycin-resistant E. faecium, while in-
fections due to vancomycin-resistant E. faecalis and
Enterococcus spp. with intrinsic glycopeptid resistance
e.g. E. gallinarum remain rare [2, 32]. (iii) Since we
used surveillance definitions to determine infections,
in some cases of UTIs the identified VRE might have
been a contamination rather than the infection-causing
pathogen. (iv) Finally, we had no information regarding
strain characteristics, therefore local or regional out-
breaks cannot be excluded.
Conclusion
To proportion of vancomycin-resistant enterococcal in-
fections has emerged as a relevant threat for patients
and the healthcare system in Germany. Particularly the
increasing rate of VRE in blood stream infections pose a
serious threat for patients. Although specific recommen-
dations and efforts regarding prevention of nosocomial
infections, transmission of VRE and improvement in
antimicrobial prescription are in place in Germany, the
proportion of VRE continues to increase. To this end,
implementation of effective strategies are necessary in
order to reduce the spread of VRE.
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